Precision Biosciences (DTIL) Share-based Compensation (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Share-based Compensation of $1.5 million for Q1 2026, down 45.11% year-over-year from $2.8 million in Q1 2025, and up 119.64% quarter-over-quarter from -$7.9 million in Q4 2025.
Precision Biosciences (DTIL) Share-based Compensation (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Share-based Compensation for 9 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 45.11% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at -$1.0 million (down 108.29% YoY), while the FY2025 annual figure was $259000.0, down 97.95% from the prior year.
- Share-based Compensation advanced to $1.5 million in Q1 2026 per DTIL's latest filing, from -$7.9 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $16.7 million in Q3 2024 and bottomed at -$7.9 million in Q4 2025.
- Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 437.84% — and 2025, when it slumped 320.83%.
- Precision Biosciences' Share-based Compensation stood at $4.5 million in 2022, then sank by 34.55% to $3.0 million in 2023, then rose by 20.28% to $3.6 million in 2024, then tumbled by 320.83% to -$7.9 million in 2025, then jumped by 119.64% to $1.5 million in 2026.
- Business Quant data shows DTIL's Share-based Compensation at $1.5 million in Q1 2026, -$7.9 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.01 Bn | 132.16 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.18 Bn | 55.04 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.55 Bn | 28.24 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.19 Bn | 26.36 Bn | - | - |
| 10 | Precision Biosciences | 225.21 Mn | 137.66 Mn | - | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.84 Mn |
| Jun 30, 2026 | 1.84 Mn |
| Mar 31, 2026 | 1.55 Mn |
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | -7.89 Mn |
| Dec 31, 2025 | -7.89 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Mar 31, 2025 | 2.82 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Dec 31, 2024 | 3.57 Mn |
| Sep 30, 2024 | 16.70 Mn |
| Sep 30, 2024 | 16.70 Mn |
| Jun 30, 2024 | 2.93 Mn |
| Jun 30, 2024 | 2.93 Mn |
| Mar 31, 2024 | 2.91 Mn |
| Mar 31, 2024 | 2.91 Mn |